Search results
Results from the WOW.Com Content Network
Montelukast is an inhibitor of the drug metabolizing enzyme CYP2C8, part of the cytochrome P450 system. Therefore, it is theoretically possible that the combination of montelukast with a CYP2C8 substrate (e.g. amodiaquine, an anti-malarial drug) could increase the plasma concentrations of the substrate.
The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone, according to FDA slides reviewed by Reuters.
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
An antileukotriene, also known as leukotriene modifier and leukotriene receptor antagonist, is a medication which functions as a leukotriene-related enzyme inhibitor (arachidonate 5-lipoxygenase) or leukotriene receptor antagonist (cysteinyl leukotriene receptors) and consequently opposes the function of these inflammatory mediators; leukotrienes are produced by the immune system and serve to ...
Over the last 20 years, research into the effects of specific drugs has become almost exclusively funded by drug companies that have an interest in the results. The government, through agencies such as the National Institutes of Health, sponsors generic research related to various diseases, but beyond that initial stage, most of the work is ...
Cromolyn Nedocromil. Mast cell stabilizers are medications used to prevent or treat certain allergic disorders. They block mast cell degranulation, stabilizing the cell and thereby preventing the release of histamine and related mediators.
Ozempic also has hormonal effects that regulate appetite and influence your brain's sense of reward when it comes to food, resulting in fewer cravings and an average weight loss of 11 pounds in ...
The move will have direct implications for Joy Reid, the anchor who currently fills 7 p.m. She is expected to host her last show on MSNBC this week. More from Variety.